Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Rejects Calls To Extend Clinical Trial Regulation Transition Period

Sponsors Worried About Member State Preparedness Are Reminded About Tacit Approval

Executive Summary

A senior European Commission official has a clear answer for those expecting the mandatory phase of the EU Clinical Trial Regulation to be delayed. There is no such plan on the cards.

You may also be interested in...

Mandatory Use Of ‘Dysfunctional’ EU Clinical Trial Portal Raises Concern In Germany

Efforts are on to address the “serious deficiencies” raised by the German associations for medical ethics committees, trial sponsors, contract research organizations and other stakeholders regarding the EU Clinical Trial Information System that will become mandatory from 31 January 2023.

EU Promises ‘Unifying’ Stakeholder Forum To Discuss Changes To Clinical Trial Landscape

The new workplan for the EU's initiative on accelerating clinical trials lays out the timelines for a set of “priority actions,” such as mapping the European clinical trial environment and establishing a consolidated process for more efficiently managing scientific advice on trials.

So Far So Good: EU Member States On ‘Limited’ Experience With Clinical Trial Portal

At a recent webinar on the EU Clinical Trial Information System (CTIS), representatives from different EU member states said the new system was working well and highlighted certain “good practices” for study sponsors to consider. 

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts